Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCLUDE: Insulin Degludec vs Insulin Glargine U300 in T2DM
NCT03078478Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2017; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03078478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078478.